Fiscal Year 2025 Department of Defense Rare Cancers Research Program (RCRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Concept Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: HT942525RCRPCA	Investigators at or above the level of postdoctoral fellow	 Supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Proof-of-concept is the anticipated outcome. Reviewers will be blinded to the identity of the Principal Investigator, collaborators, and their organization(s). Submission must address at least one of the FY25 focus areas of Biology, Research, and/or Therapy. Preliminary data are not required. Clinical trials are not allowed. Submission of a letter of intent is required prior to full application submission. 	 The maximum allowable funding for the entire period of performance is \$140,000 for total costs (direct plus indirect costs). The maximum period of performance is 2 years. 	Pre-Application (Letter of Intent): July 22, 2025 5:00 p.m. Eastern time Application: August 26, 2025 11:59 p.m. Eastern time
Idea Development Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: HT942525RCRPIDA	Independent Investigators at or above the level of Assistant Professor	 Promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation in the rare cancers field. Impact is a key criterion of this award mechanism. Applications that demonstrate exceptional scientific merit but lack high potential impact do not meet the intent of the award mechanism. Submission must address at least one of the FY25 focus areas of Biology, Research, and/or Therapy. Preliminary data with disease-specific rationale is required. However, these data do not necessarily need to be derived from studies of the proposed rare cancer type(s)/subtype(s) under study and may include correlative studies to ongoing clinical research. Clinical trials are not allowed. Pre-application submission is required; application submission is by invitation only. 	 The maximum allowable funding for the entire period of performance is \$490,000 for total costs (direct plus indirect costs). The maximum period of performance is 3 years. 	Pre-Application (Preproposal): July 1, 2025 5:00 p.m. Eastern time Application: October 6, 2025 11:59 p.m. Eastern time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Resource and Community Development Award Go to: • Program Announcement	Independent Investigators at or above the level of Assistant Professor	Supports the development of research resources and clinical or preclinical data sets that advance the field of rare cancers research and ultimately improve outcomes of individuals with rare cancers.	 The maximum allowable funding for the entire period of performance is \$1,120,000 for total costs (direct plus indirect costs). The maximum period of performance is 4 years. 	Pre-Application (Preproposal): July 1, 2025 5:00 p.m. Eastern time Application: October 6, 2025 11:59 p.m. Eastern time
 General Application Instructions Grants.gov Funding Opportunity Number: HT942525RCRPRCDA 		• Emphasizes development of collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians, and other members of the rare cancers community.		
		• Submission must address the FY25 focus area of Platform Development.		
		 Preliminary data are not required but may be included. 		
		 Clinical trials are not allowed. Pre-application submission is required; application submission is by invitation only. 		